Last Update 15 Jul 26
Fair value Increased 2.06%EW: CMS TAVR Coverage Expansion Will Drive Future Structural Heart Upside
Edwards Lifesciences' analyst fair value estimate has moved slightly higher to $98.92 from $96.92 as analysts factor in higher price targets in the $100 to $110 range, supported by views of stable procedure volumes, growing TAVR adoption, and potential benefits from the proposed CMS TAVR coverage changes.
Analyst Commentary
Recent Street research around Edwards Lifesciences clusters around higher price targets and constructive views on execution in transcatheter therapies, while still flagging a few areas for investors to watch. The focus is on how the company converts TAVR and broader structural heart opportunities into sustained growth and how that lines up with current valuation levels.
Bullish Takeaways
- Bullish analysts are lifting price targets into the US$100 to US$110 range, reflecting confidence that Edwards Lifesciences can support higher valuation assumptions with its current growth pipeline in TAVR and related therapies.
- Several firms highlight stable procedure volumes and healthy capital expenditure trends in MedTech, which they view as a supportive backdrop for Edwards Lifesciences to execute on its structural heart portfolio.
- The proposed CMS TAVR coverage changes are viewed as a clear positive, with analysts pointing to expanded eligibility, reduced procedural requirements, and lower barriers for new TAVR programs as potential drivers of incremental case volumes over time.
- Bullish analysts also point to growing appetite for balloon expandable TAVR, competitive share gains, and a steady ramp in transcatheter mitral and tricuspid therapies, which they see as important contributors to Edwards Lifesciences' long term growth profile.
Bearish Takeaways
- Some research points to a "mixed setup" for the broader medical device and diagnostic sector, which could limit how much valuation investors are willing to assign to Edwards Lifesciences even with supportive fundamentals.
- A portion of the commentary around the TAVR national coverage proposal is only incrementally positive, with one firm maintaining a Market Perform stance and a US$87 price target, suggesting that not all analysts see current valuation as compelling.
- Competitive dynamics remain a watchpoint, particularly as Edwards Lifesciences' ECLIPTIS system enters left atrial appendage exclusion and faces established products, which could influence how quickly the company can scale newer procedure categories.
- While multiple firms raise targets, some prior adjustments in the sector include both upward and downward moves, indicating that execution and policy benefits will likely be scrutinized closely in upcoming quarters before investors fully credit more aggressive growth assumptions.
What's in the News for Edwards Lifesciences
- Edwards Lifesciences presented extensive new clinical data at New York Valves 2026, including PROGRESS trial insights on moderate aortic stenosis and long term durability results for the SAPIEN platform across aortic, mitral, and tricuspid therapies. The company also received FDA approval for the SAPIEN 3 pulmonic valve system and reported strong Q1 2026 sales in TAVR and transcatheter mitral and tricuspid therapies (source: New York Valves 2026 conference coverage).
- The company agreed to pay a US$10 million penalty to the Federal Trade Commission related to its acquisition of JC Medical, with additional requirements to implement an antitrust compliance program and provide prior notice before future TAVR-AR related acquisitions, as part of a broader US$12 million settlement that also involves Genesis MedTech Group (source: FTC enforcement action).
- Edwards Lifesciences is scheduled to report second quarter results, with analysts cited in recent coverage expecting a single digit earnings rise. This follows Q1 2026 results that were described as stronger than expected and accompanied by higher 2026 guidance and continued adoption of the SAPIEN TAVR platform, EVOQUE, PASCAL, and SAPIEN M3 (source: earnings preview coverage).
- Recent index changes place Edwards Lifesciences in the Russell 1000 Value Defensive Index, Russell 1000 Defensive Index, Russell Midcap Index, and Russell Midcap Value Benchmark, while the stock has been removed from the Russell Top 200 Index and Russell Top 200 Value Benchmark (source: index constituent updates).
- New long term data from the COMMENCE aortic trial reported 10 year outcomes for surgical valves using RESILIA tissue, including high freedom from structural valve deterioration and reoperation. These results add to Edwards Lifesciences’ broader evidence base alongside the PARTNER trial series for SAPIEN TAVR and SAVR therapies (source: COMMENCE trial update).
Valuation Changes for Edwards Lifesciences
- Fair Value: The analyst fair value estimate for Edwards Lifesciences has risen slightly to $98.92 from $96.92.
- Discount Rate: The discount rate has fallen slightly to 7.43% from 7.47%, indicating a modest change in the risk assumptions used in the model.
- Revenue Growth: The long term revenue growth assumption is now 9.61% compared with 9.63% previously, a very small adjustment.
- Net Profit Margin: The projected net profit margin has edged lower to 25.89% from 26.02%, reflecting a slightly more conservative view on future profitability for Edwards Lifesciences.
- Future P/E: The future P/E multiple assumption has risen modestly to 31.0x from 30.2x, indicating a slightly higher valuation multiple applied to projected earnings.
0 viewsusers have viewed this narrative update
Key Takeaways
- Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share.
- Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.
- Tariffs, competitive pressures, and strategic investments could impact Edwards Lifesciences' margins and revenue growth, requiring careful financial planning to achieve targets.
Catalysts
About Edwards Lifesciences- Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future.
- The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
- The recent approval of the Sapien M3 in Europe as the world's first transcatheter mitral valve replacement system signals Edwards' ability to address large, unmet patient needs, which could result in substantial revenue growth.
- Edwards' ongoing investments in surgical innovation, such as the RESILIA tissue technology, are likely to expand access and adoption of its cardiovascular therapies globally, potentially improving net margins and bolstering revenue.
- The company's plan to mitigate the financial impacts of announced tariffs and the JenaValve acquisition while maintaining its EPS guidance of $2.40 to $2.50 demonstrates an operational efficiency that could positively impact earnings.
Edwards Lifesciences Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Edwards Lifesciences's revenue will grow by 9.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from 17.1% today to 25.9% in 3 years time.
- Analysts expect earnings to reach $2.1 billion (and earnings per share of $3.78) by about July 2029, up from $1.1 billion today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 31.0x on those 2029 earnings, down from 46.7x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.6x.
- Analysts expect the number of shares outstanding to decline by 1.92% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.43%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Edwards Lifesciences faces potential financial risks due to the impact of tariffs, which could affect the company's gross margins and net earnings, as they anticipate a $0.05 EPS impact from current tariffs in 2025, with greater impacts expected in 2026.
- The acquisition of JenaValve may lead to an EPS dilution of $0.05 to $0.10, which could strain operating margins and necessitate careful planning to offset the acquisition costs in order to maintain earnings per share targets.
- The competitive pressure in international markets, such as Japan, is exerting downward pressure on TAVR procedure growth, potentially impacting revenue growth and expansion efforts in these regions.
- While Edwards anticipates expanding TAVR indications to asymptomatic patients, the regulatory and policy changes required for this may take longer than expected, delaying the projected revenues from this expanded patient base.
- High levels of discretionary R&D spending, as well as necessary strategic investments to offset EPS impacts, indicate that operating expenses could rise, potentially impacting net profit margins if the expected growth in revenues does not materialize accordingly.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $98.92 for Edwards Lifesciences based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $84.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $8.3 billion, earnings will come to $2.1 billion, and it would be trading on a PE ratio of 31.0x, assuming you use a discount rate of 7.4%.
- Given the current share price of $87.27, the analyst price target of $98.92 is 11.8% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Edwards Lifesciences?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives